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ABSTRACT 
Background 
Tobacco smoking is highly prevalent among people attending treatment for a 
substance use disorder (SUD). In the UK, specialist support to stop smoking is largely 
delivered by a national network of Stop Smoking Services, and typically comprises of 
behavioural support delivered by trained practitioners on an individual (one-to-one) or group 
basis combined with a pharmacological smoking cessation aid.  We evaluate the cost-
effectiveness of these interventions, and compare cost-effectiveness for interventions using 
group- and individual-based support, in populations under treatment for SUD.  
Methods 
Economic modelling was used to evaluate the incremental cost-per-quality adjusted life 
years (QALYs) gained for smoking cessation interventions compared to alternative methods 
of quitting for the SUD treatment population. Allowance was made for potentially lower 
abstinence rates in the SUD population.   
Results 
The incremental cost per QALY gained from quit attempts supported through more 
frequently provided interventions in England ranged from around £4,700 to £12,200. These 
values are below the maximum cost-effectiveness threshold adopted by policy makers in 
England for judging whether health programmes are a cost-effective use of resources.  The 
estimated cost-per QALY gained for Interventions using group-based behavioural support 
were estimated to be at least half the magnitude of those using individual support due to 
lower intervention costs and higher reported quit rates. Conclusions reached regarding the 
cost-effectiveness of group-based interventions were also found to be more robust to 
changes in modelling assumptions.        
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Conclusions 
Smoking cessation interventions were found to be cost-effective when applied to the SUD 
population, particularly when grouped-based behavioural support is offered alongside 
pharmacological treatment.        
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IMPLICATIONS 
This analysis has shown that smoking cessation interventions combining pharmacological 
treatment with behavioural support can offer a cost-effective method for increasing rates of 
smoking cessation in populations being treated for a substance use disorder. This is despite 
evidence of lower comparative success rates in terms of smoking abstinence in populations 
with SUD.  Our evaluation suggests that medication combined with group-based behavioural 
support may offer better value for money in this population compared to interventions using 
individual support, though further evidence on the comparative effectiveness and cost of 
interventions delivered to SUD treatment populations would facilitate a more robust 
comparison.         
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BACKGROUND 
Tobacco smoking is highly prevalent among people attending treatment for a substance use 
disorder (SUD).1 In the UK, specialist support to stop smoking is largely delivered by a 
national network of Stop Smoking Services, and typically comprises of behavioural support 
delivered by trained practitioners on an individual (one-to-one) or group basis combined with 
a pharmacological smoking cessation aid.  While these services are generally regarded as a 
cost-effective public health intervention when applied to the general population, 2,3 economic 
evaluations of smoking cessation interventions in more vulnerable groups have been less 
frequent.  This paper reports an economic evaluation of the cost-effectiveness of smoking 
cessation interventions applied to SUD treatment populations.  
 
METHODS 
Analytical approach 
We evaluated smoking cessations interventions within a cost-per quality-adjusted life year 
(“cost-utility”) framework.4 A key statistic in economic evaluation is the incremental cost-
effectiveness ratio (ICER). In a cost-utility analysis this measures the additional cost per 
extra quality- adjusted life years that are gained from a health programme compared to its 
next best alternative.  Quality-adjusted-life-years (QALYs) are a widely used metric of health 
outcome in economic analysis. They combine, in a single measure, the impact on life-
expectancy and/or the quality of life years lived attributable to health interventions.   
We adopted a cost-utility framework as it is one of a number of economic approaches 
currently recommended by NICE for evaluating whether public health interventions deliver 
value for money.5  Evidence-based economic modelling to estimate ICERs applicable to 
smokers attending SUD treatment programmes for specialist smoking cessation 
interventions most frequently provided by stop smoking services across England. These 
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include: medication (single or combination NRT or varenicline) combined with either 
specialised group or individual (one-to-one) behavioural support.  Our evaluation presents a 
broad assessment of average intervention cost-effectiveness within the population of 
interest, largely because some of the evidence inherent to our modelling of cost-
effectiveness (e.g. mortality risks) relate to the SUD treatment population as a whole. Our 
findings are therefore more likely to be weighted towards more commonly presenting and 
prevalent substance use disorders within the population seeking treatment.    
Incremental costs and QALYs for each intervention are measured in comparison to the cost 
and QALY outcomes associated with other methods of quitting that might have been chosen 
to support a current quit attempt in the absence of an intervention.  For this evaluation we 
assumed that these alternative “treatment as usual” methods include unsupported quit 
attempts or use of “over-the-counter” nicotine replacement products (OTC NRT). Both are 
reported to have broadly the same abstinence rate (around 4%),6 which is significantly below 
rates of success reported for interventions delivered through stop smoking services. 7  Our 
evaluation also adjusted separately for the presence of a “background quit rate”.3,8 This 
refers to the possibility that, in the absence of a current quit attempt supported through 
whichever means, future attempts to quit smoking might still otherwise be undertaken. 
Failure to account for this will overstate the QALY benefits of current attempts to quit 
smoking.         
For our evaluation we define the ICER for each type of smoking cessation intervention as:  
(Ci – Cc)/(Qi – Qc)  
Ci is the cost of delivering a smoking cessation intervention and Cc is the cost of the 
alternative method of quitting. For this evaluation we examined cost-effectiveness from the 
perspective of English local government authorities who currently commission and pay for 
smoking cessation interventions delivered through stop smoking services. The evaluation is 
therefore inclusive of the costs of providing medication and behavioural support that local 
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authorities will pay for directly, but excludes consideration of any out-of-pocket expenses for 
OTC NRT or other expenditures made by smokers through unsupported attempts to quit. 
Therefore, for the incremental analysis reported here, Cc is assumed to be zero.     
Similarly Qi and Qc are, respectively, the gain in QALYs over time that would be expected 
from a current quit attempt (adjusting for the background quit rate) aided by a smoking 
cessation intervention and the alternative quit method.  Both Qi and Qc can in turn be defined 
as:    
Qlife-time cessation * p 
Qlife-time cessation is the gain in QALYs that a current smoker would enjoy if they were to quit 
smoking permanently at any given age, and p is the rate at which life-time cessation is 
achieved through use of smoking cessation interventions or their alternatives.   
Our evaluation used simulation modelling of the QALY impacts of permanent cessation 
combined with reported evidence on the costs and effectiveness (in terms of abstinence 
rates) of smoking cessation interventions and alternative methods of quitting. The modelling 
adjusted for lower expected abstinence rates for smokers in SUD treatment compared to 
rates observed for non-SUD populations.9,10 It also assumes that smokers with an SUD 
would stand to gain less from quitting smoking in terms of gains in quality-adjusted life 
expectancy due to the less favourable survival prognosis expected for SUD populations due 
to additional non-tobacco related risks to health associated with SUD (e.g. for opiate users 
accidental overdose and risks of intravenous drug use).11     
To evaluate whether the estimated ICERs point to smoking cessation interventions being  
cost-effective when applied to the SUD treatment population, they were compared to the 
maximum cost per QALY threshold of £20,000 to £30,000 currently adopted in England by 
the National Institute for Health and Care Excellence (NICE) for assessing whether health 
care and public health interventions represent value for money in these terms12.  
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We report a “base-case” evaluation of cost-effectiveness based on a specific set of 
evidence-based assumptions regarding the value of different modelling parameters. We also 
tested, through a sensitivity analysis, the extent to which cost-effectiveness conclusions from 
the base-case evaluation were sensitive to deviations from modelling assumptions.    
All modelling for the economic evaluation was carried out in Microsoft Excel (2010 version).  
Modelling and base-case assumptions 
For the “base-case” analysis our approach to quantifying the QALYs that a smoker  in 
treatment for SUD would gain if they quit smoking centred  on using current evidence on the 
mortality and health effects of smoking to estimate the proportional gain in QALYs that would 
be expected from quitting in the wider population of smokers. We then separately modelled 
the total remaining QALYs expected for continuing smokers attending SUD treatment and, 
combining this with the estimated proportional QALY improvement expected from smoking 
cessation, estimated the absolute gain in QALYs that would result if a smoker with SUD 
were to quit. In taking this approach we implicitly adjust for the impact of a less favourable 
underlying survival (and therefore QALY) prognosis for smokers with SUD on the expected 
health-related benefits of quitting smoking in this population.         
Modelling the proportional gain in QALYs from smoking cessation  
To estimate the proportional gain in QALYs afforded through smoking cessation we used 
evidence on the mortality and health-related quality of life impacts of smoking applicable to 
the wider population to quantify the QALYs expected for a hypothetical cohort of continuing 
smokers and a cohort of quitters (for both cohorts n=1000).  
We have assumed that quitters stopped smoking between 35 and 44 years of age as this 
age group best matched the average age profile of clients attending SUD structured 
treatment programmes in England: for opiate-only clients and clients using non-opiates and 
alcohol combined the median age is 39 and 34 years respectively, though the median age 
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for clients attending treatment for non-opiate use only (29 years) is below the selected age 
band13.  Life years survived for both cohorts were simulated over a 40 year time horizon, the 
period over which mortality data were available from the specific study we chose to inform 
assumptions regarding risk of death for continuing smokers and quitters across different age 
groups (see below).       
We chose a widely cited British study by Doll et al14 into the mortality impacts of smoking to 
inform our modelling of survival smokers and quitters. Evidence from this study has also 
been used to inform mortality risk assumptions in previous economic evaluations of smoking 
cessation activity8,15.  A limitation is that the study was that it was restricted to examining the 
effects of smoking in a specific cohort of male doctors followed-up over a 50 year period 
between 1951 and 2001 and may therefore not be entirely representative of wider population 
mortality risks.  The modelling described here used the mortality rates reported by Doll et al 
for continuing smokers from age 35 to 44 onwards and for former smokers across different 
ages who quit smoking within that age band.  These rates were used to estimate the number 
of person years of survival at each age over the 40 year time horizon within each cohort.    
For each cohort QALYs were estimated by weighting simulated year of survival by age-
specific health state “utility” weights reported for current and former regular smokers 
16.These were based on data from the 2006 Health Survey of England 17 which asked 
respondents sampled from the general population to report their health status using the EQ-
5D instrument 18. As well as being from drawn from a nationally representative survey, these 
data have the advantage that the EQ-5D instrument was designed specifically for yielding 
health state weights suitable for estimating QALYs. It characterises health across five 
dimensions (mobility, self-care, usual activity, pain/discomfort and anxiety/depression) and at 
three levels within each dimension. Each possible health state has a corresponding utility 
weight based on how a sample of respondents from the British general population rated a 
core sample of 243 unique health states when compared to “full health” (scored as 1) and 
death (scored as zero).18  A disadvantage is that the data will potentially understate the 
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health state differential between continued smoking and extended periods of smoking 
cessation that began in the age group of interest as health state information by age of 
quitting is not presented.         
To calculate remaining QALYs for continuing smokers and a quitters the weighted life years 
for each cohort were summed over the 40 year time horizon and divided by 1000 (the initial 
size of each simulation cohort) to estimate average remaining QALYs.  Following 
convention, future QALYs acquired through smoking cessation were discounted to reflect the 
lower relative value placed on future quality-adjusted years of life lived: the recommended 
discount rate applicable to health programmes in England is 3.5% 19. 
The proportional gain in (discounted) QALYs due to smoking cessation was then calculated 
as: 
[Remaining QALYs for quitter – Remaining QALYs for continuing smoker] ÷ Remaining 
QALYs for continuing smoker) 
Modelling QALYs for smokers in SUD treatment 
To estimate remaining QALYs for a smoker attending SUD treatment we again modelled 
person years survived over a 40 year time period, in this case for a hypothetical SUD 
treatment cohort (n=1000). This required an estimate of the mortality rate at differing ages 
that reflects not only deaths associated with continued tobacco use but also the wider health 
risks linked to SUD.  
To determine these rates we used published age-specific standardised mortality ratios 
(SMRs) estimated for n=10,927 SUD treatment cases identified from electronic patient 
records for a large NHS mental health service provider in England.20 These SMRs measure 
the relative risk of death for identified cases compared to that for comparable age groups in 
the general population of England and Wales. To estimate absolute mortality rates for the 
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SUD treatment population the SMRs were multiplied by corresponding age-specific death 
rates reported in national death statistics for England and Wales.21    
Given that the SMR data used were specific to a particular service-area locality they may not 
be wholly representative of mortality risks nationally for SUD treatment participants.  They 
also relate to risk of mortality on a patient case register that will be inclusive of a non-
smoking minority, where tobacco smoking prevalence could be variable depending on the 
type of SUD being treated.22  As such these estimates are likely to be a conservative 
measure of morality risk for smokers attending treatment for SUD and will, by implication, 
over-estimate remaining life expectancy. This in turn will have a tendency to inflate our base-
case estimate of the absolute gain in QALYs from smoking cessation for the SUD treatment 
population (using the estimated proportional gain in QALYs linked to smoking cessation).  
To estimate future QALYs for the cohort of smokers in treatment for SUD, person years of 
survived at different ages were again weighted by a health state utility score.  An initial 
weighting of 0.65 (full health = 1; death =0) was applied to the simulated years survived for 
smokers attending SUD treatment aged 35 and 44 years. This weighting was taken from a 
national evaluation of drug treatment programmes in England 23,24 25 and is the mean pre-
treatment health state utility score reported by study participants using the short form 12 
(SF12) health survey instrument.23  The SF12 measure includes assessment of physical 
function, limitations in role due to physical or emotional problems, the effect of pain 
on normal work and activities, general health, vitality, impact of physical or emotional 
problems on social activities, and mental health.  A primary motivation for using this 
evidence was that it provided health state information suitable for QALY estimation within the 
population of interest. The utility weights relate to a large SUD treatment sample (n=1762) 
drawn from all new treatment episodes presenting at 342 treatment sites across England26.  
A limitation was that consent to participation in the survey led to some reported differences 
in characteristics between the survey sample and the wider SUD treatment population.25  
12 
 
To account for declining health status with age, years of survival at older ages were given a 
lower health state weighting. In the absence of direct evidence on the rate of health 
depreciation among smokers with SUD, it was assumed that health status would depreciate 
with age at a similar rate to that observed for smokers in the general population albeit from a 
lower base-level. The initial 0.65 weighting for the 35 to 44 age group was therefore 
depreciated at a rate equivalent to the differences in health state utility scores reported for 
smokers sampled from the general population at different ages for the Health Survey of 
England. 16  This yielded health state utility weightings ranging from 0.62 for life years lived 
between ages 45 to 54 to 0.53 for ages 75 to 84.  Expected remaining QALYs for a 
continuing smoker in treatment for SUD were then estimated as the (discounted) sum of the 
health state weighted years of survival.    
The absolute gain in QALYs due to smoking cessation in the SUD treatment population was 
subsequently calculated by multiplying the proportional improvement in QALYs attributable 
to smoking cessation described earlier by the remaining discounted QALYs modelled for 
continuing smokers attending SUD treatment.  
Life-time smoking cessation rates for interventions 
To estimate life-time cessation rates for interventions we have used continuous abstinence 
rates over 52 weeks from the instigation of a quit attempt reported for interventions most 
frequently provided by English stop smoking services 6. These rates were inferred from 
separately reported estimates of intervention effects,7,27 including the results from a 
statistical analysis of clinically validated 4-week abstinence data obtained from over 125,000 
treatment episodes during 2009-2010 across 24 stop smoking services.7  While 
comprehensive, these average estimates do mask variability in success rates between 
different services7 .  Furthermore, as the data used to model 4-week abstinence rates were 
extracted from administrative data systems, it is unclear to what extent unmeasured 
confounding may have biased the estimated effects.    
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Our base-case analysis assumed that 52-week abstinence rates for the SUD treatment 
population would be half the magnitude of the estimates reported for the wider population 
attending smoking cessation services. This is based on evidence that quit rates in this 
population could be as low as 50% of those reported for populations without SUD 9,10. While 
this amounts to a reasonable base-case assumption given the evidence, a draw-back 
neither of the two studies used to support the 50% assumption were based on data from 
populations in SUD treatment: one study examined the association between illicit drug use 
and smoking cessation in a population attending treatment services for tobacco addiction9, 
the other compared cessation between users and non-users of illicit drugs using data from a 
national household survey.10    
To estimate life-time smoking cessation rates for different interventions, 52-week abstinence 
rates were multiplied by an estimate of the rate of life-time continued abstinence beyond 52 
weeks. This was based on a long-term smoking relapse rate of 0.35 reported in other 
smoking cessation studies 3. This value was again halved to reflect lower expected life-time 
cessation rates in the SUD population.  
Abstinence rates for unsupported quit attempts and over-the-counter NRT  
For the base-case analysis it was assumed that, in the absence of receiving a stop smoking 
intervention, a quit attempt would either be made unsupported or through use of over the 
counter NRT.  Evidence suggests that, for smokers in the general population, these methods 
are associated with a 52-week quit rate of 4%.6 This was translated into a life-time cessation 
rate using the same assumptions regarding long-term relapse described above. 
Life-time cessation rates for specific smoking cessation interventions and for the alternative 
quit methods are summarised in table 1.  These are shown for the general population of 
smokers attending smoking cessation services (based directly on the published evidence) 
and the adjusted estimates applicable to smokers attending SUD treatment, which formed 
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the base-case assumptions regarding intervention abstinence rates for the economic 
evaluation.       
Adjusting for the “background quit rate” 
To adjust for the background quit rate in tobacco using population we deflated the estimated 
QALYs associated with smoking cessation using the same adjustment factors adopted in a 
previous cost-effectiveness analysis of smoking cessation activity applied to the general 
population 3.  This used: 1. an estimate of age-specific future cessation rates (2.5% of 
smokers per annum14) which was halved (in line with evidence cited earlier) to reflect the 
expectation of lower quit rates in the SUD population; and 2. an estimate of the proportion of 
the life-extending benefits from current successful quit attempts (0.24)3 that could be 
reasonably attributed to cessation achieved in future years, adjusting for evidence that 
quitting at future (older) ages will afford less life-extending impact.  
Intervention costs 
The costs per quit attempt supported through each smoking cessation intervention were 
taken from published indicative estimates of the average cost per treatment episode for each 
type of intervention, where one treatment episode corresponds to one attempt to quit. 6. The 
costs relate resources used to deliver intensive multi-session behavioural support (with 
prescribed NRT or varenicline) provided by specialist clinics operating through the national 
stop smoking services network.  They exclude National Health Service (NHS) non-specialist 
clinics that provide less intensive behavioural support for smoking cessation either in primary 
care or hospital-based settings. All costs were inflated using a hospital and community 
health services inflation index for England28 and are reported in UK pounds at 2015/2016 
prices (see table 1).    
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Sensitivity analysis 
We tested the sensitivity of cost-effectiveness conclusions reached to changes in base-case 
assumptions regarding the following: 52-week abstinence rates for the wider population 
accessing stop smoking services; the magnitude of the proportional downward adjustment 
made to 52-week abstinence rates for the wider population in order to estimate a base-case 
abstinence rate for the SUD treatment population; QALY gains from smoking cessation in 
the SUD treatment population; and the cost of each smoking cessation intervention.     
The sensitivity analysis was carried out by comparing base-case assumptions against the 
“tipping point” values for the parameters listed.  The tipping points identify the value specific 
parameters must take for ICERs to equate to the lower end of the maximum acceptable cost 
per QALY threshold used by NICE to gauge health programme cost-effectiveness (£20,000). 
The greater the deviation of tipping point values from the base-case assumptions the greater 
the confidence that can be placed in the cost-effectiveness conclusions given modelling 
uncertainty.   
A recent report into the suitability of the threshold set by NICE has argued for the adoption of 
a lower maximum threshold closer to £13,000 per QALY gained (effectively a more stringent 
test of whether health programmes should be recommended for funding on cost-
effectiveness grounds).29 We therefore also tested the extent to which the adoption of this 
alternative threshold affected cost-effectiveness conclusions, as well as the gap between the 
new implied tipping point values linked to the lower threshold and the base-case modelling 
assumptions.   
RESULTS 
QALY gains from smoking cessation 
Table 2 reports the estimated discounted QALYs over a 40 year time horizon for continuing 
smokers and smokers who quit between ages 35 and 44 years and the implied QALY gains 
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from smoking cessation. These estimates are presented separately for the general 
population (used to estimate the proportional increase in QALYs associated with quitting 
smoking) and SUD treatment population.  
Quitting smoking at age 35 to 45 in the general population was estimated to generate a 16% 
increase in discounted QALYs lived (c.11.3 QALYs for permanent quitters vs. c.9.8 QALYs 
for continuing smokers). If this proportional increase also applies to the SUD treatment 
population, continuing smokers would see their remaining QALYs increase from 6.4 to 7.4 – 
a gain of 1 QALY through permanent smoking cessation.  The final column of table 2 
presents estimated QALY gains from smoking cessation after adjusting for the background 
quit rate (used to estimate ICERs).  
Intervention cost-effectiveness 
Table 3 reports the expected incremental QALY gains for the SUD treatment population for 
each smoking cessation intervention over use of either unsupported quit attempts or OTC 
NRT to support a current quit attempt.  Combining these values with intervention costs, 
figure 1 presents the resulting ICERs.  
All ICERs are below the current cost threshold adopted by NICE.  They range from £4,700 
(combination NRT with group support) to £12,200 (single NRT with individualised support) 
per QALY gained.  All Interventions using group support combined with medication were 
estimated to cost less per QALY gained compared with those using individual support on 
account of the former being less costly and having higher reported abstinence rates at 52 
weeks.      
Sensitivity analysis 
Base-case and tipping point values for identified parameters, assuming a maximum 
threshold of £20,000 to £30,000 per QALY gain, are shown in table 4. In parentheses we 
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also present the corresponding tipping points when a cost-effectiveness threshold of 
£13,000 is applied. 
The difference between tipping point and base-case parameter values were larger for 
interventions combining medication with grouped-based compared to those using individual-
focussed behavioural support.  This would imply that, relatively speaking, cost-effectiveness 
conclusions for the former are likely to less sensitive and more robust to any deviation from 
our main modelling assumptions.  While all ICERs were below the lower alternative £13,000 
cost-per QALY threshold, only small to modest changes in base-case assumptions would be 
needed for ICERs relating to interventions that use individual behavioural support to equal or 
exceed this threshold. In contrast, the corresponding tipping point values relating to 
interventions involving group-based support suggest that relatively larger deviations from 
base-case values would be required to change conclusions regarding cost-effectiveness by 
increasing the cost-per QALY estimates above this lower threshold.       
DISCUSSION 
An economic evaluation of smoking cessation support applied to smokers undergoing 
treatment for a substance use disorder has shown that, compared to unsupported quit 
attempts or use of over-the-counter products, the incremental cost per QALY gained for 
interventions commonly provided by stop smoking services across England were below a 
maximum cost-effectiveness threshold used to determine whether health programmes offer 
value for money.  
Interventions using group-based support combined with medication were estimated to cost 
less per QALY gained compared to those using individual behavioural support.  Moreover, a 
sensitivity analysis suggested that more confidence can be placed in the cost-effectiveness 
conclusions regarding the former given modelling uncertainty.       
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Study limitations 
Our evaluation of intervention cost-effectiveness did not consider sub-group variability in 
intervention cost-effectiveness. For example, smokers presenting for treatment could differ in 
terms of life-expectancy and health state prognosis depending on their primary substance of 
use (e.g. cannabis versus opiate use). There may also be variation in the extent to which 
different treatment sub-groups engage and respond to interventions and achieve abstinence. 
Both these factors imply that the health impacts of interventions, and therefore their cost-
effectiveness, could also be variable.             
Our conclusions suggest that interventions that use medication combined group-based 
support may be more cost-effectiveness and less sensitive to modelling uncertainty, 
compared to those that use individual support.  The caveat to add to this is that, in our base-
case modelling, we applied evidence regarding the effectiveness and costs of interventions 
applicable to the wider population of smokers seeking help to quit. It may be that people with 
SUD respond differently to these alternative modes of behavioural support, as revealed 
through smoking abstinence rates, which will impact on the incremental QALY benefits of the 
interventions. Further evidence on the comparative effectiveness of medication combined 
with alternative approaches to delivering behavioural support in the SUD and other 
vulnerable populations would add further insight to this.     
The sensitivity analysis we conducted was deterministic and did not, through a more 
sophisticated probabilistic analysis, gauge the impact of sampling error in relation to 
important parameter values extracted from the literature.  This means that we were unable to 
evaluate in more detail the probability of intervention cost-effectiveness given this type of 
uncertainty, and the extent to cost-effectiveness probabilities varied depending on the value 
of the maximum cost-effectiveness threshold adopted.       
Finally, we did not consider the wider health care resource implications of increasing 
smoking cessation in the SUD treatment population. Partly this was because our evaluation 
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was carried from a local authority payer perspective, and therefore did not to set out to 
consider resource impacts affecting health care providers.  However, we would also note the 
difficulty in establishing whether smoking cessation increases or reduces overall health care 
resource use over time. This will depend on the comparative magnitude of cost savings 
arising from avoidance of smoking-related illness and the cost increasing effects of 
extending life-expectancy for smokers who quit, given a likely increased utilisation of medical 
care with age.30      
CONCLUSION 
Interventions that combine specialist behavioural support with medication are a cost-
effective means of promoting smoking cessation in the SUD treatment populations, though 
based on the this evaluation the economic case appears stronger for interventions that use 
specialised group- rather than individual-based behavioural support.           
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Table 1 
Base-case assumptions: intervention abstinence rates and costs 
 General population attending smoking 
cessation services 
 
SUD treatment population 
 
 
Cost of interventions6  52 week continuous 
abstinence rate6 
  
Life-time abstinence rate 
52 week continuous 
abstinence rate 
 
Life-time abstinence rate 
Single NRT with individual support 0.15 0.01 0.08 0.02 £192 
Single NRT with group support 0.20 0.13 0.10 0.03 £124 
Combination NRT with individual support 0.20 0.13 0.10 0.03  
£215 
Combination NRT with group support 0.26 0.17 0.13 0.04 £146 
Varenicline with individual support 0.24 0.16 0.12 0.04  
£311 
Varenicline NRT with group support 0.31 0.20 0.16 0.05 £242 
 
Unsupported quit attempt/OTC NRT 
 
0.04 
 
0.03 
 
0.02 
 
0.007 
 
£0 
 
 
Table 2  
Base-case assumptions: remaining QALYs (discounted) for continuing smokers and quitters and QALY gain from life-time smoking 
cessation 
 Remaining QALYs  
 
QALY gain from life-time 
cessation 
 
QALY gain from life-time 
cessation (adjusted for 
“background quit rate”) 
  
 
Continuing smoker 
 
 
Quitter 
Wider population (age 35 to 44) 9.760 11.295 1.535 1.132 
SUD treatment population (age 35 
to 44) 6.412 7.421 1.009 0.876 
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Table 3 
Base-case assumptions: incremental QALY gains for interventions (compared to unsupported quit attempts/OTC NRT) 
 Incremental QALY gain 
Single NRT with individual support 0.0157 
Single NRT with group support 0.0228 
Combination NRT with individual support 0.0228 
Combination NRT with group support 0.0313 
Varenicline with individual support 0.0285 
Varenicline NRT with group support 0.0384 
 
 
Table 4  
Sensitivity analysis: tipping point values assuming maximum cost-effectiveness threshold of £20,000 to £30,000 per QALY gained 
(tipping point values assuming maximum threshold of £13,000 per QALY gained shown in parenthesis)  
 52 week abstinence rate 
for interventions (for 
wider population using 
stop smoking service) 
52 week abstinence rate for 
unsupported quit 
attempt/OTC NRT 
(counterfactual) 
Proportional reduction in 
abstinence rates to adjust 
for presence of SUD 
QALY gain from 
permanent smoking 
cessation (SUD 
treatment population) 
 
 
Intervention cost 
 Base case 
assumption 
Tipping point Base case 
assumption 
Tipping 
point 
Base case 
assumption 
Tipping 
point 
Base case 
assumption 
Tipping 
point 
Base case 
assumption 
Tipping 
point 
Single NRT with individual support  
0.15 
 
0.11 (0.14) 
 
0.04 
 
0.08 (0.05) 
 
0.50 
 
0.39 (0.48) 
 
0.88 
 
0.54 (0.83) 
 
£192 
 
£315 (£204) 
Single NRT with group support 0.20 0.08 (0.11) 0.04 0.16 (0.13) 0.50 0.26 (0.32) 0.88 0.24 (0.37) £124 £458 (£297) 
Combination NRT with individual 
support 
 
0.20 
 
0.12 (0.16) 
 
0.04 
 
0.12 (0.08) 
 
0.50 
 
0.34 (0.43) 
 
0.88 
 
0.41 (0.64) 
 
£215 
 
£458 (£297) 
Combination NRT with group 
support 
 
0.26 
 
0.09 (0.12) 
 
0.04 
 
0.21 (0.18) 
 
0.50 
 
0.24  (0.30) 
 
0.88 
 
0.20 (0.31) 
 
£146 
 
£629 (£409) 
Varenicline with individual support  
0.24 
 
0.15 (0.21) 
 
0.04 
 
0.13 (0.07) 
 
0.50 
 
0.37 (0.46) 
 
0.88 
 
0.48 (0.74) 
 
£311 
 
£572 (£372) 
Varenicline NRT with group 
support 
 
0.31 
 
0.12 (0.17) 
 
0.04 
 
0.23 (0.18) 
 
0.50 
 
0.28 (0.35) 
 
0.88 
 
0.28 (0.42) 
 
£242 
 
£772 (£502) 
 
  
 
